Status:
COMPLETED
Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity
Lead Sponsor:
Endo Pharmaceuticals
Conditions:
Cellulite
Laxity; Skin
Eligibility:
FEMALE
18-55 years
Brief Summary
All participants who completed the EN3835-224 study will be invited to participate in this observational study to evaluate long term durability of response and safety.
Eligibility Criteria
Inclusion
- Have participated in and completed study EN3835-224 (parent study).
- Be willing and able to cooperate with the requirements of the study.
Exclusion
- Has received any collagenase treatments (eg, Santyl® Ointment) at any time since
- Has had any surgery, invasive procedure (eg, liposuction), injectable treatment (eg, KYBELLA®) or any similar treatment in the area treated during the EN3835-224 study since the completion of that study.
- Has any other conditions that, in the investigator's opinion, might indicate the participant to be unsuitable for the study
Key Trial Info
Start Date :
January 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 12 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05249257
Start Date
January 25 2022
End Date
September 12 2022
Last Update
January 19 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Endo Clinical Trial Site #2
Coral Gables, Florida, United States, 33146
2
Endo Clinical Trial Site #3
Metairie, Louisiana, United States, 70006
3
Endo Clinical Trial Site #1
New York, New York, United States, 10021